



EPIC Online Technology Meeting on Biosensors

Luc Scheres CTO

E

W

info@surfix.nl +31 85 488 1285 www.surfix.nl



Photonic chip technology

Asymmetric Mach-Zehnder Interferometer (aMZI)


- Robust TriPleX based Si_3N_4 waveguides, having very low propagation loss (down to 0.1 dB/m), embedded in SiO_2
- High sensitivity (> 2000 nm/RIU)
- Operated at 850 nm

Biosensing

- Evanescent fields extends few 100 nm into solution
- Analyte binding causes phase shift
- Low limit of detection (<pM)
- Multiplexing

Miniaturization

- Potential for low-cost Point of Care applications
- Hybrid integration of VCSEL light source and PD detectors on-chip
- Wafer scale manufacturing of complete biophotonic array



Luc Scheres

EPIC Online Technology Meeting on Biosensors

Nanocoating technology

State of the art

- Uniform nanocoating and biofunctionalization
- Analyte binds everywhere, which limits sensor performance

The facts

- Si₃N₄ waveguides are narrow and make up <1% of surface area
- Analyte binding to surrounding SiO₂ remain undetected
- Unstirred liquid layer near the surface (thickness >1 μ m)
- Analyte transport in solution is governed by slow diffusion
- Depletion of analyte near the surface, especially at low concentrations


Selective nanocoating

- Concentrating analyte on the Si₃N₄ waveguides
- Higher sensitivity and reproducibility, especially at low analyte concentrations
- Lower LoD


Luc Scheres


Confidential

EPIC Online Technology Meeting on Biosensors



SURFIX






Biomarker technology

SURFIX



DNA based early cancer detection


- Small fragments of hypermethylated DNA in urine
- Detection of low pM concentrations of small target DNA fragments (5-10 kDa) demonstrated






Protein based cancer detection

Multiplexed detection of recombinant TGFBI (A) and POSTN (B) demonstrated





COVID-19 testing

Home > News & events > Leading Dutch biochip companies accelerate development of fast and reliable COVID-19 test

LEADING DUTCH BIOCHIP COMPANIES ACCELERATE DEVELOPMENT OF FAST AND RELIABLE COVID-19 TEST 24-04-2020

> Surfix B.V., together with its shareholders Qurin Diagnostics B.V. and LioniX International B.V., already successfully developing bio-photonic nanochips for cancer detection and other applications, today announce an accelerated development plan to allow mass-scale COVID-19 diagnosis and immunity detection with the financial support and in close collaboration with PhotonDelta.

The desktop testing device will yield reliable test results within 5 minutes and is scheduled to be available for commercial exploitation within 6-9 months. The device will be built around a photonic biochip using LioniX' mature and proven silicon nitride based integrated optics technology (TriPleX**), a key technology within the PhotonDelta ecosystem. The surface functionalization and biochemical assay development are provided by Surfix and Qurin Diagnostics, respectively. The combination of these disciplines enables a successful, fast and accurate virus detection platform. The development will be supported by and in tight collaboration with Photon Delta (a Dutch public private partnership). The PhotonDelta support will be both in co-funding as in further future upscaling and exploitation.

Luc Scheres

DIAGNOSTICS